We administered countercontrol behavioral therapy for sleep-maintenance insomnia to 34 insomniacs--ranging in age from 35 to 78 years--in small groups. Twenty-two subjects received immediate and 12 received delayed treatment. Three self-report measures of sleep disruption were collected on daily sleep diaries at baseline, termination of treatment, 1-month follow-up, and 12-month follow-up. Although amount of time awake at night was correlated with age (r = .50), response to treatment was not. Even though older people experienced more time awake after sleep onset prior to treatment, they were able to profit from therapy as well as the younger insomniacs. Countercontrol therapy reduced the sleep complaint for the total group by about 30% at the end of treatment, with gradual improvement continuing through a 4-week follow-up. Nevertheless, it appears that sleep-maintenance insomnia may be more difficult to treat than sleep-onset problems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037//0882-7974.1.3.233 | DOI Listing |
Br J Gen Pract
January 2025
Amsterdam UMC Locatie Meibergdreef, Vrije Universiteit, Department of General Practice, Amsterdam, Netherlands.
Background: Low-dose amitriptyline and mirtazapine are widely prescribed off-label for insomnia disorder. However, evidence from placebo-controlled studies is lacking.
Aim: To assess the effectiveness of low-dose mirtazapine and amitriptyline in patients with insomnia disorder.
BJPsych Open
December 2024
Norton College of Medicine, SUNY Upstate Medical University, New York, USA.
Neurol Sci
November 2024
Department of Psychiatry, National Center for Mental Disorders, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, China.
Background: Insomnia is a common sleep disorder affecting approximately 10-20% of adults worldwide. Despite various available treatment modalities, significant gaps remain in improving sleep maintenance and reducing functional impairments.
Objective: To systematically review and synthesize studies on the efficacy and safety of Dimdazenil for the treatment of insomnia.
Behav Sleep Med
January 2025
Department of Neurology, Neuroscience Center, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
Sleep Med
December 2024
Department of Psychology, Sapienza University of Rome, Rome, Italy. Electronic address:
Insomnia, i.e., difficulties in sleep onset and sleep maintenance, may increase the risk of anxiety symptoms, although long-term follow-up studies are rarely reported.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!